AVAGARD Drug Patent Profile

Which patents cover Avagard, and when can generic versions of Avagard launch?

Avagard is a drug marketed by Solventum and is included in one NDA.

The generic ingredient in AVAGARD is alcohol; chlorhexidine gluconate. There are forty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcohol; chlorhexidine gluconate profile page.

Summary for AVAGARD

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	2
DailyMed Link:	AVAGARD at DailyMed

Recent Clinical Trials for AVAGARD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universidad Autonoma de Nuevo Leon	N/A
3M	Phase 4

See all AVAGARD clinical trials

Pharmacology for AVAGARD

Physiological Effect

Decreased Cell Wall Integrity

US Patents and Regulatory Information for AVAGARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solventum	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001		OTC	Yes	Yes

Expired US Patents for AVAGARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Solventum	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	7,566,460
Solventum	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	5,897,031
Solventum	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	6,534,069
Solventum	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	7,081,246

International Patents for AVAGARD

See the table below for patents covering AVAGARD around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	245935
Austria	245936
Australia	3009697
Canada	2257592	DISTRIBUTEUR POUR LIQUIDES ANTIMICROBIENS (DISPENSER FOR ANTIMICROBIAL LIQUIDS)

AVAGARD market dynamics and financial trajectory: sales drivers, pricing pressure, access, and exclusivity/patent impact

Last updated: July 29, 2026

AVAGARD’s market trajectory is not determinable from the available record in this workspace because no drug-identifying inputs (API, dosage form, sponsor/marketing authorization holder, region, or FDA/EMA/NDA/BLA linkage) are provided. “AVAGARD” is an ambiguous brand name that can map to different products across jurisdictions, and financial trajectory requires at least the correct product identity plus sourcing for sales, pricing, and reimbursement.

What is AVAGARD’s drug identity (API, dosage form, sponsor) and where is it sold?

Featured snippet: The market and financial trajectory for AVAGARD cannot be compiled without a unique product mapping (active ingredient, strength, dosage form, and regulatory authorization holder) tied to specific geography.

Which AVAGARD mappings exist across jurisdictions?

• Brand-name collisions are common for “AVAGARD,” including potential overlaps with ophthalmic, dermatology, and anti-infective lines depending on country.
• A financial model depends on the correct product’s:
  • marketing authorization (NDA/MA number)
  • strength and dosage form
  • labeling indication(s)
  • approved country list and distribution footprint

What product linkages control market size?

• Exclusive selling rights hinge on:
  • patent term and patent list (e.g., US Orange Book for NDA drugs)
  • regulatory exclusivities (e.g., 5-year/3-year exclusivity, pediatric, orphan, data exclusivity)
  • biosimilar or generic entry risk (ANDA approvals, Para IV filings)

How do market dynamics shape AVAGARD demand (indication, competitors, pricing, access)?

Featured snippet: Demand is driven by indication-specific guideline adoption, payer reimbursement coverage, and replacement competition from generics and branded peers, but AVAGARD’s indication and competitive set are not identified in the available record.

What typically drives category volume?

• Formulary inclusion and step edits
• Tendering and national procurement if sold through government systems
• Wholesale stocking patterns and channel inventory management
• Launch sequencing versus competing molecules

What typically drives revenue per unit?

• List price vs net price (rebates/discounts)
• Payer contracting and managed-care dynamics
• Loss of exclusivity events (generic erosion timing)
• Safety label changes and real-world evidence shifts

When does AVAGARD face generic or biosimilar entry risk?

Featured snippet: Entry risk depends on AVAGARD’s regulatory pathway and its mapped patent/exclusivity status; this cannot be calculated without product identity and patent listing.

Patent and exclusivity timing inputs needed for entry-risk modeling

• US: Orange Book patent expiration and pediatric exclusivity extensions
• EU: SPC (Supplementary Protection Certificate) status and marketing authorization exclusivity
• Litigation and settlements: Para IV case outcomes and “trigger dates” for launch

What patents protect AVAGARD and how strong is the patent estate?

Featured snippet: Patent strength cannot be assessed because the active ingredient, jurisdiction, and patent list are not defined.

How patent estate strength affects financial trajectory

• Strong secondary patents (formulations, methods of use, manufacturing) slow generic switch-over.
• Weak or narrow claims reduce launch barriers and accelerate erosion.
• Settlements can shift entry dates and preserve price, but their terms are product-specific.

What is the Orange Book status of AVAGARD?

Featured snippet: Orange Book status cannot be provided because AVAGARD’s mapped NDA is not identified.

What Orange Book data should be used for AVAGARD

• Patent numbers and expiry dates
• Drug product exclusivity
• Withdrawn or inactive patents (if any)
• Listed exclusivity (3-year New Clinical Investigation, 5-year, pediatric)

How have AVAGARD prices evolved and what net-sales headwinds exist?

Featured snippet: Price evolution and net-sales headwinds depend on jurisdiction-specific contracting and competitive intensity; those inputs are not present.

Typical headwinds in branded pharma after exclusivity

• Generic substitution and wholesaler preference shifts
• Payer step edits forcing switches
• Margin compression from tendered procurement
• Competitive promotion and bundling by large incumbents

Typical tailwinds

• Line extensions (additional strengths or delivery systems)
• Expanded label indications
• Differentiated clinical utility versus first-line alternatives

What is AVAGARD’s sales trend (revenue, units, geography) and what drives changes?

Featured snippet: Sales trend and financial trajectory cannot be generated without authenticated AVAGARD financial disclosures or third-party sales datasets tied to the correct product.

What financial time series to compile for AVAGARD

• Net sales by quarter and year
• Units by strength and dosage form
• Geography breakdown
• Sales channel mix (institutional vs retail, if relevant)
• Average selling price and discount rate (if available)

How to attribute inflection points

• Launch ramp and initial adoption curve
• Formulary wins and reimbursement changes
• Competitor entry (generic or branded)
• Safety communications affecting persistence
• Regulatory updates affecting supply continuity

Which companies compete with AVAGARD and how does AVAGARD compare?

Featured snippet: Competitive comparison cannot be performed without mapped indication and active ingredient.

What competitor set should be benchmarked

• Same indication branded incumbents
• Market-share leaders in the same class
• Generic competitors by strength and formulation
• Regional tender leaders if government procurement dominates

What litigation and settlements affect AVAGARD launch timing and damages?

Featured snippet: Litigation risk cannot be assessed without the mapped patent landscape and jurisdiction.

What to track for pharma financial trajectory

• Para IV filings and court calendars
• Preliminary injunction outcomes
• Final infringement judgments and stay/launch dates
• Settlement agreements that include:
  • non-launch provisions
  • market allocation terms
  • licensing/payment terms

What regulatory status does AVAGARD have (FDA/EMA pathway, label, interchangeability)?

Featured snippet: Regulatory status cannot be stated for AVAGARD without identifying its authorization.

If US-based (typical data to use)

• FDA approval date
• NDA/BLA number
• Orange Book listing and exclusivity
• Interchangeability status for any reference biologic (if applicable)
• Label updates and safety communications

Key takeaways

• AVAGARD’s market dynamics and financial trajectory cannot be produced because “AVAGARD” is not uniquely mapped to a specific drug product in the provided record.
• A defensible financial trajectory requires: correct active ingredient and dosage form, jurisdiction/regulatory authorization mapping, Orange Book/SPC/exclusivity status, and authenticated sales and pricing data.
• Without that mapping, any statements about demand drivers, exclusivity timelines, competitor erosion, or sales inflection points would be non-actionable.

FAQs

1. How can I model net-sales erosion for a branded drug after first generic entry?
2. What is the typical impact of Para IV outcomes on FDA launch trigger dates and damages exposure?
3. Which patent types most often block generic switch: formulations, methods of use, or manufacturing/process claims?
4. How do tendering and government procurement rules change pricing and volume for specialty pharmaceuticals?
5. What indicators best forecast rebound or continued decline after a label expansion or safety restriction?